---
schema_version: "secwatch.filing_event.v1"
accession: "0001558370-22-018894"
form_type: "8-K"
ticker: "PLX"
cik: "0001006281"
company_name: "Protalix BioTherapeutics, Inc."
filed_at: "2022-12-21T23:59:59+00:00"
generated_at: "2026-06-21T00:38:54.608038+00:00"
event_type: "other"
sentiment: "neutral"
materiality_score: 0.3
calibrated_materiality_score: 0.3
confidence: "high"
source: SEC EDGAR
---

# Protalix BioTherapeutics voluntarily delists from Tel Aviv Stock Exchange; NYSE American listing unaffected

## Summary
- Company requested immediate delisting of common stock from TASE; effective three months from request.
- Stock continues trading on TASE during the three-month period; all shares expected to transfer to NYSE American.
- NYSE American listing and SEC reporting obligations remain unchanged; company will focus on U.S. capital market.
- Decision aims to reduce operating costs by having a single set of listing rules and regulations.
- No financial impact disclosed; delisting is voluntary and procedural.

## SEC filing metadata
- accession: 0001558370-22-018894
- form_type: 8-K
- ticker: PLX
- cik: 0001006281
- company_name: Protalix BioTherapeutics, Inc.
- filed_at: 2022-12-21T23:59:59+00:00
- event_type: other
- sentiment: neutral
- materiality_score: 0.3
- calibrated_materiality_score: 0.3
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1006281/000155837022018894/0001558370-22-018894-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1006281/000155837022018894/plx-20221221x8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001558370-22-018894
- JSON: https://secwatch.observer/filing/0001558370-22-018894.json
- Plain text: https://secwatch.observer/filing/0001558370-22-018894.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.